The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts
1998

Efficacy of Daunorubicin-GA3 in Ovarian Cancer

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): PHJ Houbal, E Boven, CAM Erkelens, RGG Leenders, JW Scheeren, HM Pinedo, HJ Haismal

Primary Institution: University Hospital VU University

Hypothesis

Can the prodrug DNR-GA3 be more effective than daunorubicin in treating human ovarian cancer xenografts?

Conclusion

DNR-GA3 is more effective than daunorubicin and may be particularly useful for treating tumors with necrotic areas.

Supporting Evidence

  • DNR-GA3 was 18 times less toxic than daunorubicin in vitro.
  • The maximum tolerated dose of DNR-GA3 was 6-10 times higher than that of daunorubicin.
  • In three out of four tumor lines, DNR-GA3 resulted in a maximum tumor growth inhibition from 82% to 95%.
  • DNR-GA3 treatment extended the specific growth delay in OVCAR-3 and MRI-H-207 xenografts.

Takeaway

A new drug called DNR-GA3 works better than an older drug for treating certain types of ovarian cancer in mice.

Methodology

The study compared the effects of DNR-GA3 and daunorubicin on human ovarian cancer xenografts in mice, measuring tumor growth inhibition and drug toxicity.

Limitations

The study was conducted in mice, and results may not directly translate to humans.

Participant Demographics

Female athymic nude mice were used for the experiments.

Statistical Information

P-Value

p<0.02

Statistical Significance

p<0.02

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication